Patent 5300490 Issued on April 5, 1994. Estimated Expiration Date: August 20, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/8, Glycoprotein (carbohydrate containing)514/12, 25 or more peptide repeating units in known peptide chain structure514/21, Produced by or extracted from animal tissue530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/397Glycoprotein hormones
This invention relates to a novel anticoagulant substance in human urine, a process for its preparation and a pharmaceutical composition comprising the said substance for the prevention and/or treatment of diseases related to the disorders in blood coagulation system.
Other References
Wen et al.; Human Thrombomodulin: Complete cDNA sequence and chromosome localization of the gene, Biochem., vol. 26, pp. 4350-4357 (1987)
Suzuki et al.; Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation, Embo Journal, vol. 6 (7), pp. 1891-1897 (1987)
Jackman et al.; Human thrombomodulin gene is intron depleted: Nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control, Proc. Nat. Acad. Sci. USA, vol. 84, pp. 6425-6429 (1987)
J. Biochem. 103, 281-285 (1988), Shirai et al
Thrombosis Research, 37, 353-364 (1985) Aoki et al
Yoshikawa et al.; "Protection of Endotoxin-Induced Disseminated Intravascular Coagulation in Rats by Gabexate Mesilate"; Kyoto Profectural Univ. of Med.; pp. 633-640
Ishii et al.; Yakugakkai Abstract 6F05, 11-1, 1988
Ishii et al.; "Thrombomodulin is Present in Human Plasma and Urine"; J. Clin. Invest., vol. 76, Dec. 1985, pp. 2178-2181
Palareti et al.; Thrombosis and Haemostasis; "Effects of Gabexate Mesilate, a New Synthetic Serine Protease Inhibitor on Blood Coagulation in Patients with Dic"; Jour. International Soc. on Thrombosis and Haemostasis; No. 1, vol. 58, 1987, p. 420
Schoendorf et al.; "Endotoxin-Induced Disseminated Intravascular Coagulation in Nonpregnant Rats"; Dept. of OB/GYN; NY School of Med; 1971; pp. 51-58
Ng et al.; "Pasteurization of Antihemophilic Factor and Model Virus Inactivation Studies"; Thrombosis Research 39; 1985; pp. 439-447
Zushi et al.; "The Last Three Consecutive Epidermal Growth Factor-Like Structures of Human Thrombomodulin Comprise the Minimum Functional Domain for Protein C-Activating Cofactor Activity and Anticoagulant Activity"; Jour. of Bio. Chem., vol. 264, No. 18, 1989, pp. 10351-10353
Gomi et al.; "Minimum Functional Domain of Human Thrombomodulin for Protein C Activating Cofactor Activity and Anticoagulant Activity"; Jour. of the International Soc. on Thrombosis and Haemostasis; Thrombosis; Thrombosis and Haemostasis; Abstract 1039; 1989; p. 334
Maruyama et al.; "Human Thrombomodulin is not an Efficient Inhibitor of the Procoagulant Activity of Thrombin"; J. Clin. Invest.; vol. 75, 1985; pp. 987-991
Salem et al.; "Isolation and Characterization of Thrombomodulin from Human Placenta"; Jour. Bio. Chem., 1984; vol. 259, No. 19, 1984; pp. 12246-12251
Suzuki et al.; "Functionally Active Thrombomodulin is Present in Human Platelets"; J. Biochem, 104, 1988, pp. 628-632
Robbins et al.; "Plasmin and Plasminogen Activators: Kinetics, and Kinetics of Plasminogen Activation"; Annals N.Y. Acad. of Sci., 1981; pp. 588-591
Kurosawa et al.; "A 10-KDA Cyanogen Bromide Fragment from the Epidermal Growth Factor Homology Domain of Rabbit Thrombomodulin Contains the Primary Thrombin Binding Site"; Jour. Bio. Chem; vol. 263, No. 13, 1988; pp. 5993-5996
Shirai et al.; "Gene Structure of Human Thrombomodulin, a Cofactor for Thrombin-Catalyzed Activation of Protein C"; J. Biochem., 103, 281, 1988
Sottrup-Jenson, L. et al.; "The Primary Structure of Human Plasminogen . . ."; Progress in Chemical Fibrinolysis and Thrombolysis, 3, 191, 1978
Moroz, L. A., "Mini-Plasminogen: A Mechanism for Leukocyte Modulation of Plasminogen Activation by Urokinase", Blood, 58, 97; 1978
White, W. F. et al.; "The Isolation and Characterization of Plasminogen Activators from Human Urine"; Biochemistry, 5, 2160, 1966
Bernik, M. B. et al., "Production by Human Tissues in Culture of Immunologically Distinct, Multiple Molecular Weight Forms of Plasminogen Activators"; Annals New York Acad. of Sci.; 593-608, 1981
Blauhut et al., "Substitution of Antithrombin III in Shock and Dic-A Randomized Study"; Thrombosis Research, vol. 39, No. 1, pp. 81-89, 1985
Moake, J. L., "Disseminated Intravascular Coagulation"; Current Therapy, pp. 338-339, 1989
Loscalzo; "Thrombolysis in the Management of Acute Myocardial Infarction and Unstable Angina Pectoris"; Drugs, pp. 192-204; 1985
Ohno et al., "Fibrinolytic System in Comparison with Heparin or Aprotinin"; Thrombosis Research, vol. 24, No. 5/6, pp. 445-452, 1982
Triantaphyllopoulos; "Effects of Human Antithrombin III on Mortality and Blood Coagulation Induced in Rabbits by Endotoxin"; Thromb Haemostas, vol. 51, No. 2; pp. 232-235; 1984
Iosbe, "Inhibitory Effects of Gabexate Mesilate (Foy) on Experimental Dic"; Advanced Exp. Med. Biol., pp. 385-394, 1979
Emerson, Jr. et al.; "Protection Against Disseminated Intravascular Coagulation and Death by Antithrombin-III in the Escherichia Coli Endotoxemic Rat"; Circulatory Shock; vol. 21; pp. 1-13, 1987
Diffang et al.; "Effect of Trasylol on Fibrin Deposition and Elimination in the Lungs of Rats with Intravascular Coagulation Induced by Thrombin or Thromboplastin"; Thrombosis Research, vol. 5, pp. 263-276, 1974
Suzuki, K. et al.; J. Bio. Chem., 264, 4872, 1989
Rees, M. W., et al.; Chemical Abstracts, 85, 490, Abstract No. 6027r, 197
August 20, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
